Agency Information Collection Activities; Proposed Collection; Comment Request; Financial Disclosure by Clinical Investigators, 23803-23804 [2015-09908]
Download as PDF
Federal Register / Vol. 80, No. 82 / Wednesday, April 29, 2015 / Notices
II. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
III. The Paperwork Reduction Act of
1995
This draft guidance refers to
previously approved collections of
information that are subject to review by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3520). The
collections of information in part 25
have been approved under OMB control
number 0910–0322 and the collections
of information in part 314 have been
approved under OMB control number
0910–0001.
IV. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
Workshop’’ that appeared in the Federal
Register of April 17, 2015 (80 FR
21248). The document announced a
public workshop. The document was
published with the incorrect title. This
document corrects that error.
FOR FURTHER INFORMATION CONTACT:
Leslie Wheelock, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 4345, Silver Spring,
MD, 301–796–8450, FAX: 301–847–
8106, leslie.wheelock@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of April 17, 2015, in
FR Doc. 2015–08846, on page 21248 the
following correction(s) is/are made:
1. On page 21248, in the second
column, starting at the sixth sentence of
the first paragraph, the title
‘‘Methodological Considerations to
Address Unmeasured Information
About Important Health Factors in
Pharmacoepidemiology Studies that
Rely on Electronic Healthcare Databases
to Evaluate the Safety of Regulated
Pharmaceutical Products in the
Postapproval Setting’’ is corrected to
read ‘‘Inadequate Information on
Important Health Factors in
Pharmacoepidemiology Studies Relying
on Healthcare Databases.’’
Dated: April 23, 2015.
Peter Lurie,
Associate Commissioner for Public Health
Strategy and Analysis.
[FR Doc. 2015–09966 Filed 4–28–15; 8:45 am]
BILLING CODE 4164–01–P
Dated: April 23, 2015.
Peter Lurie,
Associate Commissioner for Public Health
Strategy and Analysis.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–09869 Filed 4–28–15; 8:45 am]
Food and Drug Administration
BILLING CODE 4164–01–P
[Docket No. FDA–2012–N–0280]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Financial
Disclosure by Clinical Investigators
Food and Drug Administration
[Docket No. FDA–2015–N–0001]
AGENCY:
Addressing Inadequate Information on
Important Health Factors in
Pharmacoepidemiology Studies
Relying on Healthcare Databases;
Public Workshop; Correction
HHS.
mstockstill on DSK4VPTVN1PROD with NOTICES
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration is correcting a notice
entitled ‘‘Addressing Inadequate
Information on Important Health Factors
in Pharmacoepidemiology Studies
Relying on Healthcare Databases; Public
SUMMARY:
VerDate Sep<11>2014
17:18 Apr 28, 2015
Jkt 235001
ACTION:
Food and Drug Administration,
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
23803
notice. This notice solicits comments on
information collection on financial
disclosure by clinical investigators.
DATES: Submit either electronic or
written comments on the collection of
information by June 29, 2015.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Rd., COLE–14526, Silver
Spring, MD 20993–0002, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
E:\FR\FM\29APN1.SGM
29APN1
23804
Federal Register / Vol. 80, No. 82 / Wednesday, April 29, 2015 / Notices
Financial Disclosure by Clinical
Investigators
(OMB Control Number 0910–0396)—
Extension
Respondents to this collection are
sponsors of marketing applications that
contain clinical data from studies
covered by the regulations. These
sponsors represent pharmaceutical,
biologic, and medical device firms.
Respondents are also clinical
investigators who provide financial
information to the sponsors of
marketing applications.
Under § 54.4(a) (21 CFR 54.4(a)),
applicants submitting an application
that relies on clinical studies must
submit a complete list of clinical
investigators who participated in a
covered clinical study, and must either
certify to the absence of certain financial
15 minutes will be required for each
recordkeeper to add this record to the
clinical investigators’ file.
Under § 54.4(b), clinical investigators
supply to the sponsor of a covered study
financial information sufficient to allow
the sponsor to submit complete and
accurate certification or disclosure
statements. Clinical investigators are
accustomed to supplying such
information when applying for research
grants. Also, most people know the
financial holdings of their immediate
family and records of such interests are
generally accessible because they are
needed for preparing tax records. For
these reasons, FDA estimates that it will
take clinical investigators 15 minutes to
submit such records to the sponsor.
FDA estimates the burden of this
collection of information as follows:
arrangements with clinical investigators
(Form FDA 3454) or, under § 54.4(a)(3),
disclose to FDA the nature of those
arrangements and the steps taken by the
applicant or sponsor to minimize the
potential for bias (Form FDA 3455).
Under § 54.6, the sponsors of covered
studies must maintain complete records
of compensation agreements with any
compensation paid to nonemployee
clinical investigators, including
information showing any financial
interests held by the clinical
investigator, for a time period of 2 years
after the date of approval of the
applications. Sponsors of covered
studies maintain many records with
regard to clinical investigators,
including protocol agreements and
investigator resumes or curriculum
vitae. FDA estimates than an average of
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
responses per
respondent
Number of
respondents
21 CFR Section
Average
burden per
response
Total annual
responses
Total hours
Certification—54.4(a)(1) and (a)(2)—
Form FDA 3454 ..............................
Disclosure—54.4(a)(3)—Form
FDA
3455 ...............................................
1,000
1
1,000
1
1,000
100
1
100
5
500
Total ............................................
..............................
..............................
..............................
..................................
1,500
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
21 CFR Section
Number of
recordkeepers
Number of
records per
recordkeeper
Total annual
records
Average
burden per
recordkeeping
Total hours
Recordkeeping—54.6 ........................
1,000
1
1,000
0.25 (15 minutes)
250
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1
21 CFR Section
Number of
respondents
Number of
disclosures per
respondent
Total annual
disclosures
Average
burden per
disclosure
Total hours
54.4(b)—Clinical Investigators ...........
7,106
1
7,106
0.17 (10 minutes)
1,208
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: April 23, 2015.
Peter Lurie,
Associate Commissioner for Public Health
Strategy and Analysis.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–09908 Filed 4–28–15; 8:45 am]
National Institute of Neurological
Disorders and Stroke; Amended Notice
of Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
BILLING CODE 4164–01–P
National Institutes of Health
Notice is hereby given of a change in
the meeting of the National Institute of
Neurological Disorders and Stroke
Special Emphasis Panel, April 22, 2015,
08:00 a.m. to April 23, 2015, 06:00 p.m.,
Lorien Hotel & Spa, 1600 King Street,
VerDate Sep<11>2014
17:18 Apr 28, 2015
Jkt 235001
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Alexandria, VA, 22314 which was
published in the Federal Register on
April 3, 2015, 80FRN18241.
The meeting notice is amended to
change the location of the meeting from
the Lorien Hotel & Spa to the Hotel
Monaco Alexandria. The date and time
remain the same. The meeting is closed
to the public.
E:\FR\FM\29APN1.SGM
29APN1
Agencies
[Federal Register Volume 80, Number 82 (Wednesday, April 29, 2015)]
[Notices]
[Pages 23803-23804]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-09908]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0280]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Financial Disclosure by Clinical Investigators
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on information collection on
financial disclosure by clinical investigators.
DATES: Submit either electronic or written comments on the collection
of information by June 29, 2015.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver
Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
[[Page 23804]]
Financial Disclosure by Clinical Investigators
(OMB Control Number 0910-0396)--Extension
Respondents to this collection are sponsors of marketing
applications that contain clinical data from studies covered by the
regulations. These sponsors represent pharmaceutical, biologic, and
medical device firms. Respondents are also clinical investigators who
provide financial information to the sponsors of marketing
applications.
Under Sec. 54.4(a) (21 CFR 54.4(a)), applicants submitting an
application that relies on clinical studies must submit a complete list
of clinical investigators who participated in a covered clinical study,
and must either certify to the absence of certain financial
arrangements with clinical investigators (Form FDA 3454) or, under
Sec. 54.4(a)(3), disclose to FDA the nature of those arrangements and
the steps taken by the applicant or sponsor to minimize the potential
for bias (Form FDA 3455).
Under Sec. 54.6, the sponsors of covered studies must maintain
complete records of compensation agreements with any compensation paid
to nonemployee clinical investigators, including information showing
any financial interests held by the clinical investigator, for a time
period of 2 years after the date of approval of the applications.
Sponsors of covered studies maintain many records with regard to
clinical investigators, including protocol agreements and investigator
resumes or curriculum vitae. FDA estimates than an average of 15
minutes will be required for each recordkeeper to add this record to
the clinical investigators' file.
Under Sec. 54.4(b), clinical investigators supply to the sponsor
of a covered study financial information sufficient to allow the
sponsor to submit complete and accurate certification or disclosure
statements. Clinical investigators are accustomed to supplying such
information when applying for research grants. Also, most people know
the financial holdings of their immediate family and records of such
interests are generally accessible because they are needed for
preparing tax records. For these reasons, FDA estimates that it will
take clinical investigators 15 minutes to submit such records to the
sponsor.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of responses per Total annual Average burden per Total hours
respondents respondent responses response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Certification--54.4(a)(1) and (a)(2)--Form FDA 3454.... 1,000 1 1,000 1 1,000
Disclosure--54.4(a)(3)--Form FDA 3455.................. 100 1 100 5 500
------------------------------------------------------------------------------------------------
Total.............................................. ................. ................. ................. ................... 1,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Table 2--Estimated Annual Recordkeeping Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Number of records Total annual Average burden per
21 CFR Section recordkeepers per recordkeeper records recordkeeping Total hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Recordkeeping--54.6............................... 1,000 1 1,000 0.25 (15 minutes) 250
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Table 3--Estimated Annual Third-Party Disclosure Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of disclosures per Total annual Average burden per Total hours
respondents respondent disclosures disclosure
--------------------------------------------------------------------------------------------------------------------------------------------------------
54.4(b)--Clinical Investigators................... 7,106 1 7,106 0.17 (10 minutes) 1,208
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: April 23, 2015.
Peter Lurie,
Associate Commissioner for Public Health Strategy and Analysis.
[FR Doc. 2015-09908 Filed 4-28-15; 8:45 am]
BILLING CODE 4164-01-P